Summary:
- Sangamo Therapeutics, a biotechnology company, has announced that the U.S. Food and Drug Administration (FDA) has accepted their request for a rolling submission of a Biologics License Application (BLA) for ST-920, a potential treatment for Fabry disease.
- Fabry disease is a rare genetic disorder that affects the body's ability to break down a specific type of fat, leading to the buildup of this fat in various organs and tissues, which can cause significant health problems.
- The rolling submission process allows Sangamo to submit portions of the BLA as they become available, rather than waiting to submit the entire application at once, which can help expedite the review and potential approval of ST-920 as a new treatment option for individuals living with Fabry disease.